CL2016002125A1 - Nuevos compuestos derivados de 6,7-dihidro-3 h-oxazolo (3,4-a) pirazina-5,8-diona - Google Patents

Nuevos compuestos derivados de 6,7-dihidro-3 h-oxazolo (3,4-a) pirazina-5,8-diona

Info

Publication number
CL2016002125A1
CL2016002125A1 CL2016002125A CL2016002125A CL2016002125A1 CL 2016002125 A1 CL2016002125 A1 CL 2016002125A1 CL 2016002125 A CL2016002125 A CL 2016002125A CL 2016002125 A CL2016002125 A CL 2016002125A CL 2016002125 A1 CL2016002125 A1 CL 2016002125A1
Authority
CL
Chile
Prior art keywords
oxazolo
compounds derived
pyrazine
dione
dihydro
Prior art date
Application number
CL2016002125A
Other languages
English (en)
Inventor
Sérgio Luiz Sacurai
Carlos Eduardo Da Costa Touzarim
Fabiano Travanca Toledo
Bruno Artur De Sousa
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of CL2016002125A1 publication Critical patent/CL2016002125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3 H-OXAZOLO[3,4-a] PIRAZINA-5,8-DIONA, INHIBIDORES DE FOSFODIESTERASAS; COMPOSICION FARMACEUTICA; USO PARA EL TRATAMIENTO Y/O PROFILAXIS DE DISFUNCION ERECTIL, LITIASIS, HIPERPLASIA PROSTATICA, HIPERTENSION PULMONAR, DISFUNCION SEXUAL, ENTRE OTRAS.
CL2016002125A 2014-02-24 2016-08-23 Nuevos compuestos derivados de 6,7-dihidro-3 h-oxazolo (3,4-a) pirazina-5,8-diona CL2016002125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461943825P 2014-02-24 2014-02-24

Publications (1)

Publication Number Publication Date
CL2016002125A1 true CL2016002125A1 (es) 2016-12-30

Family

ID=53877456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002125A CL2016002125A1 (es) 2014-02-24 2016-08-23 Nuevos compuestos derivados de 6,7-dihidro-3 h-oxazolo (3,4-a) pirazina-5,8-diona

Country Status (19)

Country Link
US (1) US9359378B2 (es)
EP (1) EP3133072B1 (es)
JP (1) JP6636463B2 (es)
KR (1) KR102408431B1 (es)
AR (1) AR099523A1 (es)
AU (1) AU2015221431B2 (es)
BR (1) BR112016019609B1 (es)
CA (1) CA2940225C (es)
CL (1) CL2016002125A1 (es)
ES (1) ES2734063T3 (es)
HU (1) HUE044993T2 (es)
IL (1) IL247330B (es)
MX (1) MX369840B (es)
PL (1) PL3133072T3 (es)
PT (1) PT3133072T (es)
TR (1) TR201910896T4 (es)
UY (1) UY36010A (es)
WO (1) WO2015123748A1 (es)
ZA (1) ZA201606522B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3144770A1 (en) * 2019-07-15 2021-01-21 Biolab Sanus Farmaceutica Ltda Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
CA2940225C (en) 2021-12-28
KR102408431B1 (ko) 2022-06-13
BR112016019609B1 (pt) 2022-06-14
ZA201606522B (en) 2018-04-25
WO2015123748A1 (pt) 2015-08-27
US9359378B2 (en) 2016-06-07
US20150239903A1 (en) 2015-08-27
IL247330A0 (en) 2016-09-29
AU2015221431A8 (en) 2016-11-24
AU2015221431A1 (en) 2016-09-29
EP3133072A4 (en) 2017-08-09
AR099523A1 (es) 2016-07-27
PL3133072T3 (pl) 2019-10-31
EP3133072A1 (en) 2017-02-22
CA2940225A1 (en) 2015-08-27
JP6636463B2 (ja) 2020-01-29
TR201910896T4 (tr) 2019-08-21
PT3133072T (pt) 2019-07-26
AU2015221431B2 (en) 2018-04-19
BR112016019609A2 (es) 2017-08-22
IL247330B (en) 2020-10-29
UY36010A (es) 2015-09-30
MX369840B (es) 2019-11-22
MX2016010912A (es) 2016-11-30
JP2017506263A (ja) 2017-03-02
HUE044993T2 (hu) 2019-11-28
KR20160116028A (ko) 2016-10-06
ES2734063T3 (es) 2019-12-04
EP3133072B1 (en) 2019-05-01

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019002734A1 (es) Isoquinolinas como inhibidores de hpk1.
ES2966825T3 (es) Activadores de piruvato quinasa para su uso en el tratamiento de trastornos sanguíneos
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2008002140A1 (es) Compuestos derivados de azaindol, inhibidores jak; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos proliferativos, cardiacos, neurodegenerativo, asociados con trasplante de organos, artritis reumatoidea, entre otras.
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2011001078A1 (es) Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CO2020007895A2 (es) Inhibidores de histona acetiltransferasa de la familia myst
CL2016002839A1 (es) Derivados de carboxamida